Low power, compact charge coupled device signal processing system

A variety of charged coupled devices (CCDs) for performing programmable correlation for preprocessing environmental sensor data preparatory to its transmission to the ground were developed. A total of two separate ICs were developed and a third was evaluated. The first IC was a CCD chirp z transform IC capable of performing a 32 point DFT at frequencies to 1 MHz. All on chip circuitry operated as designed with the exception of the limited dynamic range caused by a fixed pattern noise due to interactions between the digital and analog circuits. The second IC developed was a 64 stage CCD analog/analog correlator for performing time domain correlation. Multiplier errors were found to be less than 1 percent at designed signal levels and less than 0.3 percent at the measured smaller levels. A prototype IC for performing time domain correlation was also evaluated

Electrokinetic Potentials at Liquid Surfaces

Aqueous solutions of potassium chloride were allowed to flow through air. The solutions were from 10-1 N to 10-7N. The hydrostatic pressure was from 23 to 80 cm. of solution. The flow was vertical and laminar, through a circular aperture in a thin platinum disc on to a second platinum disc. The diameter of the aperture was 0.05 cm. The discs served as electrodes. The potential difference was measured with a vacuum tube potentiometer. A F.P. 54 G. E. tube was used, so the potential difference was measured with essentially no current flow

NCAM (CD56) Expression in keratin-producing odontogenic cysts: aberrant expression in KCOT

Background: Keratin-producing odontogenic cysts (KPOCs) are a group of cystic lesions that are often aggressive, with high rates of recurrence and multifocality. KPOCs included orthokeratinised odontogenic cyst (OOC) and parakeratotic odontogenic cysts, which are now considered true tumours denominated keratocystic odontogenic tumours (KCOTs). GLUT1 is a protein transporter that is involved in the active uptake of glucose across cell membranes and that is overexpressed in tumours in close correlation with the proliferation rate and positron emission tomography (PET) imaging results. Methods: A series of 58 keratin-producing odontogenic cysts was evaluated histologically and immunohistochemically in terms of GLUT1 expression. Different data were correlated using the beta regression model in relation to histological type and immunohistochemical expression of GLUT1, which was quantified using two different morphological methods. Results: KPOC cases comprised 12 OOCs and 46 KCOTs, the latter corresponding to 6 syndromic and 40 sporadic KCOTs. GLUT1 expression was very low in OOC cases compared with KCOT cases, with statistical significant differences when quantification was considered. Different GLUT1 localisation patterns were revealed by immunostaining, with the parabasal cells showing higher reactivity in KCOTs. However, among KCOTs cases, GLUT1 expression was unable to establish differences between syndromic and sporadic cases. Conclusions: GLUT1 expression differentiated between OOC and KCOT cases, with significantly higher expression in KCOTs, but did not differentiate between syndromic and sporadic KCOT cases. However, given the structural characteristics of KCOTs, we hypothesised that PET imaging methodology is probably not a useful diagnostic tool for KCOTs. Further studies of GLUT1 expression and PET examination in KCOT series are needed to confirm this last hypothesis. Keywords: Glucose transporter protein, Immunohistochemistry, Keratin-producing odontogenic cyst, Keratocystic odontogenic tumour, Orthokeratinised odontogenic cyst, Positron emission tomograph

Leukotriene C4 biosynthesis in isolated August rat peritoneal leukocytes

The mixed leukocyte population obtained from the peritoneum of the August rat is a potentially important experimental model of inherent eosinophilia that has not been well characterized. In the present study, isolated cell preparations generated a concentration-dependent release of leukotriene (LT) C4 when exposed to the Ca2+ ionophore A23187, reaching maximal stimulation at 5.0 μM. This response was inhibited by the 5-lipoxygenase activating protein antagonist MK-886 (0.1 μM), nominally Ca2+ and Mg2+-free incubation media and by activation of protein kinase C via phorbol 12-myristate 13-acetate (50 nM). These findings establish a model system for investigating LTC4 profiles contingent with innate peritoneal eosinophilia and are consistent with the hypothesis that cellular LTC4 biosynthesis is phosphoregulated

Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine

[This corrects the article DOI: 10.1186/s13054-016-1208-6.]

Poor Birth Outcomes Related to Cannabis Use in Pregnancy

Pregnancy, a period of dynamic physiological changes, necessitates careful consideration of external influences on maternal and fetal health. Despite increasing legalization and prevalence, the impact of cannabis use during gestation remains a topic of significant concern and investigation. Recent studies have shed light on the consequences of in utero cannabis exposure, encompassing both fetal and maternal outcomes. Notably, several studies have identified associations between cannabis exposure during pregnancy and adverse fetal outcomes, including small-for-gestational-age birth, altered neurodevelopment, preterm birth, and increased risk of neonatal morbidity. Evidence to date underscores the urgent need for education, intervention, and regulatory oversight regarding cannabis use during pregnancy. The role of pharmacists in mitigating the risks associated with cannabis use during pregnancy is paramount for the safety of the mother and fetus. Pharmacists are positioned to provide patient-centered care and can play a pivotal role in optimizing maternal and fetal health outcomes. By adhering to comprehensive medication management principles and leveraging their expertise in pharmacotherapeutics, pharmacists can help ensure the safe and appropriate use of medications during pregnancy, including the avoidance of cannabis

Analgesic efficacy of hydromorphone in American alligators (Alligator mississippiensis)

BackgroundAmerican alligators (Alligator mississippiensis) are maintained in zoos, aquaria, and farms for educational, research, and production purposes. The standard of veterinary medical care and welfare for captive reptiles requires managing pain and discomfort under conditions deemed painful in mammals. While analgesic efficacy and pharmacokinetic data for several reptile species are published, data with respect to analgesic efficacy in crocodilians are clearly lacking.ObjectiveThe objective of this study was to determine the analgesic efficacy of hydromorphone in alligators.MethodsFemale American alligators (N = 9; 57 months of age) were exposed to mechanical noxious stimuli at multiple anatomic sites using von Frey filaments ranging in size from 1.65 to 6.65 grams-force, and their behavioral reactions recorded. In order to evaluate analgesic efficacy, hydromorphone (0.5 mg/kg SC) was administered in the axillary region to the same alligators and the mechanical noxious stimuli were repeated and behaviors recorded.ResultsAdministration of hydromorphone contributed to a range from 62 to 92% reduced avoidance reactions to mechanical noxious stimuli for two anatomic sites (i.e., naris and lateral mandible, respectively).ConclusionAlligators did not appear to experience clinically relevant respiratory depression, hypothermia, or other adverse reactions. Therefore, hydromorphone shows promise as an analgesic option to be administered under painful conditions in American alligators

FDA Approval of Zuranolone: A Breakthrough Treatment for Postpartum Depression

Postpartum depression (PPD) is a serious medical condition that increases the risk of postpartum mortality and affects the ability of a postpartum individual to take care of their newborn. Until 2023, intravenously-administered brexanolone was the only Food and Drug Administration (FDA)-approved medication for PPD. Brexanolone’s route of administration poses significant barriers to accessibility and convenience. Other treatment options, such as psychotherapy and antidepressants, often require long-term commitment and may not provide rapid relief for severe symptoms. In August 2023, the FDA approved zuranolone as an oral medication for PPD, which enhances treatment accessibility and offers patients a more flexible, outpatient option. Findings from multiple clinical trials demonstrate zuranolone’s effectiveness in rapidly reducing PPD symptoms and producing significant improvements in mood and functionality within days. As a result, zuranolone represents a major advancement in PPD treatment and a promising alternative to traditional therapies for PPD patients. This review will discuss the pathophysiology of PPD, the current treatment options, challenges with the current treatment of PPD, the mechanism of action of zuranolone, pivotal clinical trials that played a role in zuranolone’s approval, the benefits and adverse effects associated with zuranolone, and future directions concerning the use of zuranolone in treating PPD